No Data
No Data
Is Centessa Pharmaceuticals (NASDAQ:CNTA) Using Too Much Debt?
Insider Sale: Chief Executive Officer of $CNTA (CNTA) Sells 1,671 Shares
Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Leerink Partners Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Announces Target Price $24
Centessa Pharmaceuticals Is Maintained at Buy by Guggenheim
Guggenheim Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $28